BiotechTube
Paragon Genomics

Paragon Genomics

Fremont, United States· Est.
paragongenomics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $37.5M

Overview

Paragon Genomics is a private, revenue-generating company specializing in NGS library preparation technology. Its core platform, CleanPlex®, is designed for targeted sequencing, offering high multiplexing capability, robustness with low-quality samples, and a streamlined workflow. The company serves both the research market and the growing clinical diagnostics sector, positioning itself as an enabler for applications in oncology, inherited disease screening, and infectious disease surveillance. Its success hinges on continued platform adoption, expansion into regulated clinical markets, and navigating a competitive landscape of established sequencing consumables providers.

OncologyInherited DiseasesInfectious Diseases

Technology Platform

CleanPlex®: A highly multiplexed PCR-based target enrichment system for next-generation sequencing (NGS), designed for high sensitivity, specificity, and uniformity from challenging, low-input samples like FFPE and cfDNA.

Funding History

3
Total raised:$37.5M
Series B$25M
Series A$10M
Seed$2.5M

Opportunities

The rapid growth of NGS in clinical diagnostics, especially in precision oncology and liquid biopsy, presents a major expansion opportunity.
The company can leverage its robust platform to develop and secure regulatory clearance for IVD kits, tapping into a higher-margin market.
Strategic partnerships with pharma for companion diagnostics or with large diagnostic labs could accelerate commercialization and provide validation.

Risk Factors

Intense competition from dominant, well-funded players like Illumina and Thermo Fisher poses a significant market capture challenge.
The regulatory pathway for clinical diagnostics is costly, lengthy, and uncertain.
Technological disruption from newer sequencing or enrichment methods could render the current platform less competitive.

Competitive Landscape

Paragon competes in the targeted NGS enrichment segment against giants like Illumina (AmpliSeq), Thermo Fisher (Ion AmpliSeq), and Agilent (SureSelect), as well as other specialists. Competition is based on panel performance (sensitivity, specificity, uniformity), workflow simplicity, cost per sample, and breadth of panel menu. Paragon's differentiation lies in the CleanPlex® chemistry's robustness with difficult samples and streamlined workflow.

More companies in Diagnostics & Precision Medicine →More companies in United States →